BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6538115)

  • 1. Enhancement of cisplatin nephrotoxicity by probenecid.
    Daley-Yates PT; McBrien DC
    Cancer Treat Rep; 1984 Feb; 68(2):445-6. PubMed ID: 6538115
    [No Abstract]   [Full Text] [Related]  

  • 2. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
    Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug nephrotoxicity].
    Nihon Jinzo Gakkai Shi; 1986 Jul; 28(7):929-46. PubMed ID: 3795607
    [No Abstract]   [Full Text] [Related]  

  • 5. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
    Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
    Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
    Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
    Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-induced nephrotoxicity.
    Meijer S; Sleijfer DT; Mulder NH; Donker AJ
    Neth J Med; 1982; 25(8):262-9. PubMed ID: 6755283
    [No Abstract]   [Full Text] [Related]  

  • 10. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.
    Hu YJ; Chen Y; Zhang YQ; Zhou MZ; Song XM; Zhang BZ; Luo L; Xu PM; Zhao YN; Zhao YB; Cheng G
    Biol Trace Elem Res; 1997 Mar; 56(3):331-41. PubMed ID: 9197929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial.
    Benoehr P; Krueth P; Bokemeyer C; Grenz A; Osswald H; Hartmann JT
    J Am Soc Nephrol; 2005 Feb; 16(2):452-8. PubMed ID: 15590762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary lysozyme, beta-2-microglobulin, and alpha-glucosidase during cisplatin therapy].
    Airoldi M; Pecchio F; Albanese F; Mastromatteo V; Gariboldi A; Di Costanzo G; Fazio M
    Boll Soc Ital Biol Sper; 1983 Mar; 59(3):392-8. PubMed ID: 9704142
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
    Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
    Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New frontiers in cancer chemotherapy: cis-platinum].
    Sulkes A; Peretz T; Rizel S; Yahalom Y; Brian S
    Harefuah; 1986 Jan; 110(2):90-3. PubMed ID: 3516812
    [No Abstract]   [Full Text] [Related]  

  • 15. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats.
    Tikoo K; Ali IY; Gupta J; Gupta C
    Toxicol Lett; 2009 Dec; 191(2-3):158-66. PubMed ID: 19723570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation of cisplatin-induced nephrotoxicity by methionine.
    Alden WW; Repta AJ
    Chem Biol Interact; 1984 Jan; 48(1):121-4. PubMed ID: 6537905
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J; Kellie SJ
    Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, a new antineoplastic drug in veterinary medicine.
    Page R; Matus RE; Leifer CE; Loar A
    J Am Vet Med Assoc; 1985 Feb; 186(3):288-90. PubMed ID: 3918977
    [No Abstract]   [Full Text] [Related]  

  • 19. Protection by ozone preconditioning is mediated by the antioxidant system in cisplatin-induced nephrotoxicity in rats.
    Borrego A; Zamora ZB; González R; Romay C; Menéndez S; Hernández F; Montero T; Rojas E
    Mediators Inflamm; 2004 Feb; 13(1):13-9. PubMed ID: 15203559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
    Cronin S; Uberti JP; Ayash LJ; Raith C; Ratanatharathorn V
    Bone Marrow Transplant; 2000 Dec; 26(11):1247-9. PubMed ID: 11149742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.